Although our results highlight the clinical significance of targeting both the EGFR and COX-2 pathways in patients with IBC, we recognize that combination treatment of EGFR and COX-2 inhibitors in breast cancer has not been clinically successful. The gene discussed is PTGS2; the disease is breast cancer.